Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Pollyea

Showing results (101-110 of 179) with videos related to

Pageof 18
Sort By:
Blood|October 27, 2018
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaCourtney D DiNardo, Keith Pratz, Vinod Pullarkat, et al.
Leukemia Research|April 23, 2019
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysisBrett Stevens, Amanda Winters, Jonathan A Gutman, et al.
Nature Cancer|April 22, 2021
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cellsBrett M Stevens, Courtney L Jones, Daniel A Pollyea, et al.
American Journal of Hematology|June 24, 2023
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 studyCourtney D DiNardo, Stéphane De Botton, Daniel A Pollyea, et al.
Leukemia|December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndromeJorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 MutationsDaniel A Pollyea, Courtney D DiNardo, Martha L Arellano, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2016
ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemiaMark A Gregory, Angelo D'Alessandro, Francesca Alvarez-Calderon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2014
Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbationsFrancesca Alvarez-Calderon, Mark A Gregory, Catherine Pham-Danis, et al.
European Journal of Haematology|June 30, 2026
Analysis of CD8 Cytotoxic T-Cells in Patients With Myelodysplastic Neoplasms and T-Cell Large Granulocyte Lymphocytic LeukemiaMakenna May, Nathaly Limon De la Rosa, Cassandra Duarte, et al.
Nature Medicine|November 14, 2018
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemiaDaniel A Pollyea, Brett M Stevens, Courtney L Jones, et al.
Pageof 18

Showing results (101-110 of 179) with videos related to

Sort By:
Pageof 18
Blood|October 27, 2018
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaCourtney D DiNardo, Keith Pratz, Vinod Pullarkat, et al.
Leukemia Research|April 23, 2019
Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysisBrett Stevens, Amanda Winters, Jonathan A Gutman, et al.
Nature Cancer|April 22, 2021
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cellsBrett M Stevens, Courtney L Jones, Daniel A Pollyea, et al.
American Journal of Hematology|June 24, 2023
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 studyCourtney D DiNardo, Stéphane De Botton, Daniel A Pollyea, et al.
Leukemia|December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndromeJorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 MutationsDaniel A Pollyea, Courtney D DiNardo, Martha L Arellano, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2016
ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemiaMark A Gregory, Angelo D'Alessandro, Francesca Alvarez-Calderon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2014
Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbationsFrancesca Alvarez-Calderon, Mark A Gregory, Catherine Pham-Danis, et al.
European Journal of Haematology|June 30, 2026
Analysis of CD8 Cytotoxic T-Cells in Patients With Myelodysplastic Neoplasms and T-Cell Large Granulocyte Lymphocytic LeukemiaMakenna May, Nathaly Limon De la Rosa, Cassandra Duarte, et al.
Nature Medicine|November 14, 2018
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemiaDaniel A Pollyea, Brett M Stevens, Courtney L Jones, et al.
Pageof 18